# Myocardial Infarction

Myocardial infarction requires immediate ECG-based triage, assay-specific serial troponin interpretation, differentiation of ischemic infarction from myocardial injury, and rapid selection of reperfusion or invasive management. Post-event care should consolidate antithrombotic therapy, ventricular assessment, rehabilitation, and secondary prevention.

**Clinical question:** How should physicians rapidly diagnose, classify, reperfuse, risk-stratify, and provide secondary prevention after myocardial infarction?

Updated: 2026-08-20T23:33:28.900461Z

## What matters in practice
- Obtain and interpret a 12-lead ECG immediately in suspected acute coronary syndrome; persistent ST-segment elevation in contiguous leads is a working STEMI diagnosis requiring reperfusion without waiting for troponin results.[6][7]
- Diagnose acute MI by acute myocardial injury with a rise and/or fall in cardiac troponin, at least one value above the assay-specific 99th-percentile upper reference limit, plus clinical evidence of ischemia; an elevated troponin alone denotes myocardial injury, not necessarily infarction.[7][9]
- Primary PCI is preferred for STEMI when it can be delivered in a timely manner; fibrinolysis is reserved for patients without timely PCI access, followed by transfer for angiography and rescue PCI when reperfusion fails.[6][18]
- NSTEMI management is risk-based: hemodynamic or electrical instability or refractory ischemia warrants urgent invasive evaluation, whereas stable patients require serial ECG/troponin assessment and structured risk assessment to guide angiography timing.[7][22]
- Before discharge, assess left ventricular function, establish antiplatelet and lipid-lowering therapy, address heart failure or ventricular dysfunction, arrange cardiac rehabilitation, and ensure risk-factor and adherence follow-up.[6][14][22]

## Confirm ischemic myocardial infarction rather than isolated injury

Troponin interpretation must be integrated with symptoms, ECG, imaging, and clinical context.

Acute MI requires evidence of acute myocardial injury—cardiac troponin rise and/or fall with at least one value above the 99th-percentile upper reference limit—plus clinical evidence of acute myocardial ischemia. The ischemic evidence may be symptoms, new ischemic ECG changes, pathologic Q waves, new loss of viable myocardium or regional wall-motion abnormality, or coronary thrombus. Troponin elevation without ischemic evidence should be classified as myocardial injury rather than MI.[7][9]

Type 1 MI reflects acute coronary atherothrombosis. Type 2 MI reflects ischemic supply-demand imbalance without acute atherothrombosis, such as tachyarrhythmia, hypotension, or anemia. Classification should change management: type 2 MI requires correction of the precipitating process and careful evaluation for underlying coronary disease rather than reflex application of a type 1 MI antithrombotic pathway.[9]
- Use the local high-sensitivity cardiac troponin assay and its validated institutional pathway; assays are not interchangeable, and diagnostic limits vary by manufacturer and sex-specific reference thresholds.[9]
- A single low high-sensitivity troponin result may support rule-out only within a validated pathway and appropriate clinical context. Early presenters and patients with ongoing symptoms require serial testing because troponin may not yet have risen.[9]
- Renal dysfunction, older age, comorbidity, and sex influence troponin concentrations and reduce the positive predictive value of a fixed 99th-percentile threshold; interpret absolute values and serial change in clinical context.[9]

*Core diagnostic distinctions in suspected myocardial infarction.[7][9]*

| Finding | Interpretation | Immediate implication |
| --- | --- | --- |
| Persistent ST-segment elevation in anatomically contiguous leads with ischemic presentation | Working STEMI/acute coronary occlusion syndrome; do not await biomarker confirmation.[6] | Activate reperfusion pathway and transfer to PCI-capable care when indicated.[6][18] |
| Troponin rise/fall above the 99th-percentile upper reference limit plus ischemic evidence | Acute MI.[7][9] | Classify STEMI versus NSTEMI and determine type 1 versus type 2 mechanism.[7] |
| Troponin elevation without ischemic evidence | Myocardial injury rather than MI.[9] | Evaluate acute versus chronic injury and treat the underlying condition. |

## Use ECG first, then serial high-sensitivity troponin

The initial ECG determines whether the patient enters an immediate reperfusion pathway.

Obtain a 12-lead ECG immediately in patients with suspected acute coronary syndrome. For STEMI, ST-segment elevation should be present in at least two contiguous leads: at least 1 mm in leads other than V2-V3; in V2-V3, thresholds are at least 2.5 mm in men younger than 40 years, 2 mm in men 40 years or older, and 1.5 mm in women.[6]

A nondiagnostic ECG does not exclude MI. NSTEMI may present with ST depression, T-wave inversion, transient ST elevation, or a normal/nonspecific tracing. Repeat ECGs are appropriate when symptoms persist or evolve. Posterior MI or persistent ST elevation should be managed as STEMI.[7][18]
- Order high-sensitivity troponin with serial testing according to the validated local protocol; serial samples are particularly important when symptom onset was within 3 hours of testing or the first result is indeterminate.[9]
- Use transthoracic echocardiography when diagnosis remains uncertain or complications are suspected, but do not delay catheterization laboratory activation for a clinical STEMI presentation.[18]
- Consider aortic dissection, pulmonary embolism, pericarditis, myocarditis, Takotsubo syndrome, vasospasm, and spontaneous coronary artery dissection when the presentation or ECG is discordant with typical type 1 MI.[18]

*ECG-directed initial action in suspected acute MI.[6][7][18]*

| ECG pattern | Clinical action |
| --- | --- |
| Persistent ST elevation or STEMI equivalent with ischemic presentation | Treat as STEMI; begin reperfusion planning immediately without waiting for troponin.[6][18] |
| No persistent ST elevation but ischemic symptoms or dynamic ST-T abnormalities | Manage as possible NSTE-ACS with serial ECGs, high-sensitivity troponin, and risk assessment.[7] |
| Nondiagnostic ECG with ongoing concerning symptoms | Repeat ECG and continue serial troponin testing; absence of initial diagnostic changes does not exclude NSTEMI.[7][18] |

## Reperfuse STEMI without biomarker delay

Time to coronary reperfusion is the central modifiable determinant of acute STEMI care.

Primary PCI is the preferred reperfusion approach for most patients with STEMI. Patients with ischemic symptoms of less than 12 hours' duration should undergo primary PCI when it can be performed within 120 minutes; patients with cardiogenic shock or acute severe heart failure warrant PCI regardless of time from symptom onset.[18]

When primary PCI cannot be delivered within 120 minutes and there is no contraindication, fibrinolysis is an alternative reperfusion strategy. Patients receiving fibrinolysis should be transferred to a PCI-capable center. Failed lysis, reocclusion, or reinfarction requires immediate angiography and rescue PCI; even apparent successful reperfusion should be followed by angiography within 2 to 24 hours.[18]
- Administer aspirin promptly unless contraindicated. In the supplied sources, aspirin loading for ACS is described as 162 to 325 mg of nonenteric-coated chewable aspirin.[17]
- Use supplemental oxygen for hypoxemia rather than routinely in normoxemic MI; routine oxygen has not shown clinical benefit in patients with oxygen saturation of at least 90%.[14]
- Avoid nitrates in hypotension, suspected right ventricular infarction, severe aortic stenosis, or recent phosphodiesterase-5 inhibitor exposure.[14]
- Use radial access preferentially when feasible for invasive management; drug-eluting stents are preferred when stenting is required.[14]

### Antithrombotic strategy

Antiplatelet selection depends on reperfusion strategy and bleeding risk. Potent P2Y12 inhibition with ticagrelor or prasugrel is preferred over clopidogrel for most patients undergoing PCI; clopidogrel is used when potent agents are contraindicated or unavailable and is the P2Y12 inhibitor described for fibrinolysis.[18]
- Prasugrel is contraindicated in patients with prior stroke or transient ischemic attack.[18]
- Parenteral anticoagulation is used with PCI and may include unfractionated heparin, low-molecular-weight heparin, bivalirudin, or fondaparinux depending on clinical setting and strategy.[18]

*STEMI reperfusion decisions.[6][18]*

| Clinical scenario | Preferred action | Key follow-through |
| --- | --- | --- |
| STEMI with timely PCI capability | Primary PCI.[6][18] | Do not delay for troponin confirmation.[6] |
| STEMI without PCI feasible within 120 minutes and no lytic contraindication | Fibrinolysis followed by transfer to PCI-capable center.[18] | Assess for reperfusion; perform rescue PCI for failed lysis.[18] |
| STEMI with cardiogenic shock or acute severe heart failure | Immediate PCI regardless of elapsed time from symptom onset.[18] | Culprit-vessel revascularization is central to management.[14][18] |

## Use instability and risk to determine invasive timing

NSTEMI is not a fibrinolysis indication; it requires antithrombotic treatment and risk-directed angiography.

NSTEMI is distinguished from unstable angina by a troponin rise above the 99th percentile in an ischemic clinical context. Because presentations range from stable injury to shock, early risk assessment directs diagnostic and therapeutic choices, including the timing of invasive coronary angiography.[7]

Urgent invasive evaluation is appropriate for refractory ischemia or hemodynamic or electrical instability. Stable patients require serial troponin and ECG assessment plus structured risk stratification to determine whether and when angiography should occur.[7][22]
- Do not use fibrinolysis for NSTEMI solely because troponin is elevated; the reperfusion strategy is reserved for persistent ST-elevation presentations.[6][7]
- Interpret elevated troponin cautiously in chronic kidney disease, structural heart disease, sepsis, tachyarrhythmia, and other causes of myocardial injury; determine whether ischemia and a type 1 coronary mechanism are present.[9]
- For stable patients with suspected NSTE-ACS, do not treat a single isolated troponin threshold as definitive; integrate serial values, ECG, symptom onset, renal function, and pretest probability.[9]

*NSTEMI triage priorities.[7][22]*

| Risk feature | Management implication |
| --- | --- |
| Refractory ischemia | Urgent invasive coronary evaluation.[7] |
| Hemodynamic instability, shock, or acute heart failure | Urgent invasive evaluation and stabilization.[7] |
| Electrical instability | Urgent invasive evaluation and arrhythmia-directed management.[7] |
| Clinically stable NSTE-ACS | Serial ECG/troponin testing and formal risk assessment to guide angiography timing.[7] |

## Build discharge care around ventricular function, ischemic risk, bleeding risk, and adherence

Every MI admission should end with a durable secondary-prevention and follow-up plan.

Before discharge, assess left ventricular function and identify residual ischemia, heart failure, arrhythmia, and mechanical complications. Persistent or recurrent angina, dyspnea, hypotension, new murmur, pulmonary edema, or shock after MI should trigger prompt evaluation for ischemic, electrical, or mechanical complications.[6][14]

High-intensity statin therapy should be initiated promptly after MI irrespective of baseline lipid level. Aspirin and a P2Y12 inhibitor are foundational after ACS, but the duration and intensity of antiplatelet treatment must be individualized against bleeding risk and the revascularization strategy.[14][22]
- Refer survivors to structured cardiac rehabilitation and ensure close follow-up for risk-factor modification, pharmacotherapy optimization, adherence, residual angina, and post-MI complications.[6]
- Use ACE inhibitor or ARB therapy when left ventricular systolic dysfunction, heart failure, hypertension, diabetes, or chronic kidney disease is present; mineralocorticoid receptor antagonism has benefit in selected patients with left ventricular dysfunction after MI.[14]
- Beta-blocker benefit is best established in patients with reduced LVEF or another compelling indication; evidence is less definitive after uncomplicated ACS with LVEF above 40%.[18]
- For patients receiving lipid-lowering therapy, monitor treatment tolerance and intensify risk reduction when residual risk remains high; the supplied sources support high-intensity statin initiation but do not provide a specific LDL-C target or dose regimen.[14]

*Post-MI discharge priorities.[6][14][18][22]*

| Priority | Action |
| --- | --- |
| Ventricular function | Assess LVEF and direct heart failure, renin-angiotensin system inhibitor, beta-blocker, and mineralocorticoid receptor antagonist decisions accordingly.[14][18] |
| Antithrombotic therapy | Continue aspirin plus an appropriate P2Y12 inhibitor after ACS; individualize duration against ischemic and bleeding risks.[14][22] |
| Lipid management | Initiate high-intensity statin therapy promptly after MI irrespective of baseline lipid levels.[14] |
| Rehabilitation and follow-up | Refer to cardiac rehabilitation and reassess adherence, symptoms, risk factors, and complications.[6] |

## Recognize post-infarction deterioration as a time-critical diagnostic problem

New instability after MI warrants immediate bedside reassessment and targeted imaging.

Major early complications include recurrent ischemia, heart failure, cardiogenic shock, brady- and tachyarrhythmias, acute mitral regurgitation from papillary muscle dysfunction or rupture, ventricular septal rupture, free-wall rupture, and pericarditis.[7][14][18] Mechanical complications may present with abrupt hemodynamic deterioration, pulmonary edema, a new murmur, or tamponade physiology; transthoracic echocardiography is central to rapid evaluation.[14]

Cardiogenic shock after MI remains high risk. In the cited review, 30-day mortality is approximately 30% and one-year mortality approximately 50%; immediate angiography and infarct-related artery revascularization are emphasized, with mechanical circulatory support considered for refractory shock in selected patients.[14]
- New acute pulmonary edema or systolic murmur after MI: evaluate urgently for acute ischemic mitral regurgitation and obtain echocardiography.[14]
- Sudden hypotension, cool extremities, or a new harsh systolic murmur: evaluate for ventricular septal rupture and involve cardiac surgery early.[14]
- Hypotension with elevated jugular venous pressure and muffled heart sounds: suspect free-wall rupture with tamponade; obtain emergent echocardiography and pursue pericardial drainage plus surgical management when indicated.[14]

*High-risk post-MI presentations requiring immediate reassessment.[14]*

| Presentation | Leading concern | Immediate evaluation |
| --- | --- | --- |
| Acute pulmonary edema with new systolic murmur | Acute ischemic mitral regurgitation or papillary muscle rupture.[14] | Urgent echocardiography and surgical assessment.[14] |
| Shock with new harsh systolic murmur | Post-infarction ventricular septal rupture.[14] | Urgent echocardiography and surgical consultation.[14] |
| Tamponade physiology after MI | Free-wall rupture.[14] | Emergency echocardiography, pericardial drainage, and surgical management.[14] |

## Reduce preventable delay through standardized acute MI pathways

Reliable systems convert evidence into time-sensitive treatment.

STEMI systems should enable prompt ECG acquisition, early catheterization laboratory activation, and coordinated transfer to PCI-capable centers. Quality-improvement initiatives using standardized pathways, feedback, and multidisciplinary coordination have improved evidence-based process measures in MI care.[1][13]

For NSTE-ACS, standardized serial-troponin pathways and explicit risk assessment can reduce diagnostic variation, but any algorithm must remain subordinate to clinical judgment in patients with high pretest probability, evolving ECG findings, or ongoing ischemia.[7][9]
- Audit ECG-to-reperfusion processes, transfer delays, antithrombotic contraindications, LVEF assessment, statin prescription, cardiac rehabilitation referral, and follow-up completion.[1][13]
- Document contraindications and patient-specific reasons for deviation from standardized treatment pathways to distinguish appropriate individualization from omission of indicated care.[13][15]

*Operational measures that support MI care quality.[1][13]*

| Care-process domain | Practical system intervention |
| --- | --- |
| STEMI recognition | ECG prioritization and coordinated activation of transport and catheterization laboratory teams.[13] |
| Guideline implementation | Multidisciplinary protocols, clinician education, audit, and feedback.[1][13] |
| Discharge reliability | Standardized secondary-prevention and cardiac rehabilitation workflows.[6][13] |

## Common questions

### What separates myocardial injury from myocardial infarction?

Myocardial injury is troponin elevation above the assay-specific 99th-percentile upper reference limit. MI requires acute injury with rise/fall plus evidence of ischemia from symptoms, ECG, imaging, or coronary thrombus.[7][9]

### Should STEMI treatment wait for a troponin result?

No. A typical ischemic presentation with persistent ST-segment elevation in contiguous leads is a working STEMI diagnosis. Activate reperfusion immediately; troponin confirms myocardial necrosis but should not delay treatment.[6]

### When is fibrinolysis appropriate for STEMI?

Fibrinolysis is an alternative when primary PCI cannot be delivered within 120 minutes and no contraindication exists. Transfer to a PCI center after lysis; perform rescue PCI for failed reperfusion and early angiography even after apparent success.[18]

### How should an elevated high-sensitivity troponin be interpreted in chronic kidney disease?

Chronic kidney disease reduces the positive predictive value of a fixed troponin threshold. Use serial values, the assay-specific upper reference limit, ischemic symptoms, ECG findings, and the clinical context rather than labeling every elevation as type 1 MI.[9]

### What must be completed before MI discharge?

Assess ventricular function and complications; establish antiplatelet and high-intensity statin therapy; address heart failure or ventricular dysfunction; refer to cardiac rehabilitation; and arrange close follow-up for symptoms, risk factors, and adherence.[6][14][22]

## References
1. Improving Quality of Care for Acute Myocardial Infarction — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/194725
2. Early Diagnosis of Myocardial Infarction with Sensitive ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa0900428
3. Prognostic Importance of Myocardial Ischemia Detected by ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199601113340201
4. Application of High-Sensitivity Troponin in Suspected ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa1803377
5. Cardiac Troponin T Levels for Risk Stratification in Acute ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199610313351801
6. ST-elevation myocardial infarction - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/150
7. Non-ST-elevation myocardial infarction — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/151
8. Acute myocardial infarction: primary angioplasty — heart.bmj.com — https://heart.bmj.com/content/85/6/705
9. Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations | Nature Medicine — www.nature.com — https://www.nature.com/articles/s41591-023-02325-4
10. Diagnosis and prognosis of myocardial infarction on a ... — www.nature.com — https://www.nature.com/articles/s41467-020-15487-3
11. Prognostic value of point-of-care testing for cardiac myosin ... — www.nature.com — https://www.nature.com/articles/s41598-026-47454-1
12. The American College of Cardiology's Guidelines Applied ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0735109705015706
13. Effect of implementing an acute myocardial infarction guideline on quality indicators - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4878596
14. Review of Current Management of Myocardial Infarction — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12429806
15. Adherence to Cardiac Practice Guidelines in the Management ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5324326
16. Evolution of the American College of Cardiology and ... - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6806052
17. Acute Myocardial Infarction - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK459269
18. Acute ST-Segment Elevation Myocardial Infarction (STEMI) — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK532281
19. What are appropriate rates of invasive procedures following acute myocardial infarction: a systematic review - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK68606
20. Contemporary Diagnosis and Management of Patients ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=
21. Myocardial Infarction - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK537076
22. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/40014670
23. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.1161%2FHYP.0000000000000065&link_type=DOI
24. 2022 AHA/ACC/HFSA Guideline for the Management of ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.1161%2FCIR.0000000000001063&link_type=DOI

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.